AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 NOV 5 - (NewsRx.com & NewsRx.net) -- Scientists have published a review of antigen-specific immunotherapy and cancer vaccines in a recent issue of the International Journal of Cancer.
"The specific activation of the immune system to control cancer growth in vivo has been a long-standing goal in cancer immunology and medical oncology. The identification of tumor-associated antigens has provided the basis for new concepts in antigen-specific immunotherapy. The first clinical trials on cancer vaccines were designed to evaluate the toxicity and objectively measurable immunologic effects in relation to clinical developments mostly in patients with metastatic disease," investigators in Germany report.
"MHC class I- and II-restricted peptide epitopes, antigenic proteins, viral constructs, mini-genes, and whole tumor cells have been used either alone or combined with different cytokines (i.e., IL-2, IL-12, GM-CSF), adjuvants (incomplete Freund's adjuvant, montanide, QS21), or with dendritic cells to induce specific immune responses in vivo," stated Elke Jager and colleagues at the Medizinische Klinik in Frankfurt. "Standardized assay systems to evaluate the immunologic effects of cancer vaccines ...
Source: HighBeam Research, Antigen-specific immunotherapy and cancer vaccines reviewed.